Scarica l'app Stockscreener
25.32
9.37%
2.17
Dopo l'orario di chiusura:
25.41
0.09
+0.36%
Precedente Chiudi:
$23.15
Aprire:
$27.29
Volume 24 ore:
4.58M
Relative Volume:
1.45
Capitalizzazione di mercato:
$1.58B
Reddito:
$14.34M
Utile/perdita netta:
$-199.00M
Rapporto P/E:
-6.4592
EPS:
-3.92
Flusso di cassa netto:
$-183.51M
1 W Prestazione:
+8.25%
1M Prestazione:
+21.85%
6M Prestazione:
+70.28%
1 anno Prestazione:
+59.05%
Intervallo 1D:
$24.84
$28.77
Intervallo di 1 settimana:
$22.11
$28.77
Portata 52W:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
25.32 | 1.44B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval - GuruFocus
UniQure Announces FDA Type A Meeting To Discuss BLA Data For Huntington's Gene Therapy - Nasdaq
US-listed shares of uniQure rise 13% premarket as FDA review talks revive hopes for Huntington's therapy - MarketScreener
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting - GuruFocus
uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ) - Seeking Alpha
uniQure prepares for FDA Type A meeting on AMT-130 - TipRanks
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy By Investing.com - Investing.com UK
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy - Investing.com
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy - Investing.com India
uniQure Announces Type A Meeting Scheduled with FDA - The Manila Times
uniQure N.V. Schedules FDA Meeting for AMT-130 Approval - TradingView — Track All Markets
FDA to review data on experimental Huntington's gene therapy at uniQure - Stock Titan
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Is uniQure N.V. stock supported by strong fundamentals2025 Risk Factors & Verified Momentum Stock Alerts - ulpravda.ru
uniQure: Now What? (NASDAQ:QURE) - Seeking Alpha
How sustainable is uniQure N.V. stock dividend payout2025 Growth vs Value & Weekly Market Pulse Alerts - ulpravda.ru
Pullback Watch: Is uniQure N.V. stock attractive for long term wealth building2025 Market Outlook & Weekly Hot Stock Watchlists - ulpravda.ru
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
How (QURE) Movements Inform Risk Allocation Models - Stock Traders Daily
QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $60 - 富途牛牛
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure NV (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure N.V. (QURE) Stock Analysis: Unveiling a 131% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How reliable is uniQure NV UQ1 stock dividend growth2025 Big Picture & Technical Pattern Based Buy Signals - moha.gov.vn
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP En - GuruFocus
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
QURE INVESTIGATION REMINDER: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
Whittier Daily News - FinancialContent
Understanding Momentum Shifts in (QURE) - Stock Traders Daily
uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
uniQure (NASDAQ:QURE) Trading 5.4% HigherWhat's Next? - MarketBeat
Gene therapy genie back in the bottle? - BioWorld MedTech
uniQure Notice of Investigation: Kessler Topaz Meltzer & - GlobeNewswire
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourage - GuruFocus
uniQure (NASDAQ:QURE) Trading Down 4.6%Here's Why - MarketBeat
Cell And Gene Therapy Leaders See Transformative Results Outweighing Industry Setbacks - Citeline News & Insights
What do analysts think about UniQure (QURE)? - MSN
What Do Analysts Think About UniQure (QURE)? - Finviz
How uniQure N.V. stock benefits from tech adoptionJuly 2025 Closing Moves & Fast Moving Stock Watchlists - Улправда
Quarterly Earnings: How uniQure N.V. stock benefits from tech adoptionJuly 2025 Setups & Reliable Breakout Forecasts - Улправда
Is uniQure N.V. stock positioned for long term growthLong Setup & Growth-Oriented Investment Plans - ulpravda.ru
What hedge fund moves indicate for uniQure N.V. (UQ1) stockJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - Улправда
Revisiting UniQure (NASDAQ:QURE) - Seeking Alpha
uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump (NASDAQ:QURE) - Seeking Alpha
uniQure (NASDAQ:QURE) Shares Up 14%What's Next? - MarketBeat
Sanders Morris Harris LLC Makes New $5.08 Million Investment in uniQure N.V. $QURE - MarketBeat
Revenue per share of uniQure N.V. – LSX:A1XDTV - TradingView — Track All Markets
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Nov 06 '25 |
Sale |
27.26 |
31,434 |
856,881 |
40,145 |
| Kaye Jack | Director |
Nov 04 '25 |
Option Exercise |
9.88 |
38,810 |
383,535 |
38,249 |
| Kaye Jack | Director |
Nov 04 '25 |
Sale |
30.34 |
38,810 |
1,177,517 |
20,439 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):